Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 57216631745
SciProfiles: 688918

Countries

Malaysia

Activities

Collapse all

Education and qualifications (4)

Universiti Putra Malaysia: Serdang, Selangor, MY

2019-02 to 2024-02 | PhD (Nanomedicine) (Department of Chemistry)
Education
Source: Self-asserted source
Yan Shan, LOO

International Medical University: Kuala Lumpur, Wilayah Persekutuan, MY

2015-08 to 2018-03 | MSc (Molecular Medicine) (School of Postgraduate Studies )
Education
Source: Self-asserted source
Yan Shan, LOO

Monash University Malaysia: Bandar Sunway, Selangor, MY

2010 to 2013 | BSc (Biotechnology) (School of Science )
Education
Source: Self-asserted source
Yan Shan, LOO

Monash University Malaysia: Bandar Sunway, Selangor, MY

2010 to 2013 | BSc (Environmental Management) (School of Science)
Education
Source: Self-asserted source
Yan Shan, LOO

Works (8)

Phytochemical-based nanosystems: recent advances and emerging application in antiviral photodynamic therapy

Nanomedicine
2025-02-16 | Journal article
DOI: 10.1080/17435889.2025.2452151
Contributors: Yan Shan Loo; Nur Aininie Yusoh; Wai Feng Lim; Chen Seng Ng; N. Idayu Zahid; Intan Diana Mat Azmi; Thiagarajan Madheswaran; Tze Yan Lee
Source: check_circle
Crossref

Voices in Molecular Pharmaceutics: Meet Yan Shan Loo, a Graduate Student Exploring Nanoformulations of Natural Products

Molecular Pharmaceutics
2024-02-05 | Journal article
DOI: 10.1021/acs.molpharmaceut.3c00927
Contributors: Yan Shan Loo
Source: check_circle
Crossref

Medicinal Benefits, Biological and Nanoencapsulation Functions of Riboflavin with its Toxicity Profile - A Narrative Review

Nutrition Research
2023-08-25 | Journal article
DOI: 10.1016/j.nutres.2023.08.010
Part of ISSN: 0271-5317
Contributors: Lee Tze Yan; Nuratiqah Farah; Voon Kin Chin; Chee Woei Lim; Pei Pei Chong; Rusliza Basir; Wai Feng Lim; Yan Shan Loo
Source: Self-asserted source
Yan Shan, LOO

Coencapsulation of Gemcitabine and Thymoquinone in Citrem-Phosphatidylcholine Hexosome Nanocarriers Improves In Vitro Cellular Uptake in Breast Cancer Cells.

Molecular pharmaceutics
2023-08-16 | Journal article
DOI: 10.1021/acs.molpharmaceut.3c00333
PMID: 37587099
Contributors: Loo YS; N. Idayu Zahid; Madheswaran T; Ikeno S; Nurdin A; Intan Diana Mat Azmi
Source: Self-asserted source
Yan Shan, LOO

Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems

Pharmaceutics
2023-05-06 | Journal article
DOI: 10.3390/pharmaceutics15051421
Contributors: Jassica S. L. Leu; Jasy J. X. Teoh; Angel L. Q. Ling; Joey Chong; Yan Shan Loo; Intan Diana Mat Azmi; Noor Idayu Zahid; Rajendran J. C. Bose; Thiagarajan Madheswaran
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Recent advances in the development of multifunctional lipid-based nanoparticles for co-delivery, combination treatment strategies, and theranostics in breast and lung cancer

Journal of Drug Delivery Science and Technology
2022-05 | Journal article
DOI: 10.1016/j.jddst.2022.103300
Contributors: Yan Shan Loo; N. Idayu Zahid; Thiagarajan Madheswaran; Intan Diana Mat Azmi
Source: check_circle
Crossref

Biomimetic bacterial and viral-based nanovesicles for drug delivery, theranostics, and vaccine applications

Drug Discovery Today
2021 | Journal article
DOI: 10.1016/j.drudis.2020.12.017
EID:

2-s2.0-85100051430

Part of ISSN: 18785832 13596446
Contributors: Loo, Y.S.; Bose, R.J.; McCarthy, J.R.; Mat Azmi, I.D.; Madheswaran, T.
Source: Self-asserted source
Yan Shan, LOO via Scopus - Elsevier

Encapsulation of berberine into liquid crystalline nanoparticles to enhance its solubility and anticancer activity in MCF7 human breast cancer cells

Journal of Drug Delivery Science and Technology
2020 | Journal article
DOI: 10.1016/j.jddst.2020.101756
EID:

2-s2.0-85084147888

Part of ISSN: 17732247
Contributors: Loo, Y.S.; Madheswaran, T.; Rajendran, R.; Bose, R.J.
Source: Self-asserted source
Yan Shan, LOO via Scopus - Elsevier

Peer review (2 reviews for 1 publication/grant)

Review activity for Biomedicine & pharmacotherapy. (2)
How many people are using ORCID?